A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Neomycin and Polymyxin B Sulfate, Bacitracin Zinc and Hydrocortisone (Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and Hydrocortisone)

Neomycin and Polymyxin B Sulfate, Bacitracin Zinc and Hydrocortisone reduces inflammation and suppresses immune responses, used across many conditions.

First FDA approval1995-10-30
Generic availableYes · 2 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$5.78/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$5.78
Across all dosage forms in distribution.
Highest NADAC
$5.78
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Neomycin and Polymyxin B Sulfate, Bacitracin Zinc and Hydrocortisone used for?

Neomycin and Polymyxin B Sulfate, Bacitracin Zinc and Hydrocortisone reduces inflammation and suppresses immune responses, used across many conditions.

Is there a generic for Neomycin and Polymyxin B Sulfate, Bacitracin Zinc and Hydrocortisone?

Yes. 2 ANDAs filed at FDA, 2 generic manufacturers currently shipping.

How much does my plan pay for Neomycin and Polymyxin B Sulfate, Bacitracin Zinc and Hydrocortisone?

Across 329 Part D plans, Neomycin and Polymyxin B Sulfate, Bacitracin Zinc and Hydrocortisone averages $5.78/unit (NADAC). Lowest available: $5.78/unit. Highest in distribution: $5.78/unit.

Is Neomycin and Polymyxin B Sulfate, Bacitracin Zinc and Hydrocortisone on the FDA shortage list?

No. Neomycin and Polymyxin B Sulfate, Bacitracin Zinc and Hydrocortisone is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.